TY - JOUR T1 - PEGylated dextran as long-circulating pharmaceutical carrier. JF - J Biomater Sci Polym Ed Y1 - 2004 A1 - Lukyanov, Anatoly N A1 - Sawant, Rishikesh M A1 - Hartner, William C A1 - Torchilin, Vladimir P KW - Animals KW - Dextrans KW - Drug Carriers KW - Female KW - Half-Life KW - Mice KW - Mice, Inbred C57BL KW - Polyethylene Glycols KW - Polymers KW - Tissue Distribution AB -

Dextran-polyethylene glycol (PEG) conjugates were synthesized by activating dextran hydroxy groups with carbonyldiimidazole, introducing amino groups by attaching ethylenediamine, and reacting amino groups with a succinimidyl-activated derivative of PEG. Conjugates with an average of 12 and 21 PEG (5 kDa) residues per single dextran (73 kDa) molecule were prepared. These conjugates have circulation half-lives of 5.3 h and 7.0 h, respectively, compared to 4.0 h for non-PEGylated dextran. The modification of dextran with PEG inhibits the uptake of polymer by the major organ of the reticuloendothelial system, the liver. Dextran-PEG conjugates may represent a convenient platform for long-circulating pharmaceutical preparations.

VL - 15 IS - 5 U1 - http://www.ncbi.nlm.nih.gov/pubmed/15264663?dopt=Abstract ER -